Literature DB >> 19546435

Risk of solid tumors and myeloid hematological malignancies among first-degree relatives of patients with monoclonal gammopathy of undetermined significance.

Sigurdur Y Kristinsson, Lynn R Goldin, Magnus Björkholm, Ingemar Turesson, Ola Landgren.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19546435      PMCID： PMC2719044          DOI： 10.3324/haematol.2009.006346

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: a population-based case-control study.

Authors:  Ola Landgren; Martha S Linet; Mary L McMaster; Gloria Gridley; Kari Hemminki; Lynn R Goldin
Journal:  Int J Cancer       Date:  2006-06-15       Impact factor: 7.396

2.  Germline CDKN2A mutation implicated in predisposition to multiple myeloma.

Authors:  D Dilworth; L Liu; A K Stewart; J R Berenson; N Lassam; D Hogg
Journal:  Blood       Date:  2000-03-01       Impact factor: 22.113

3.  Familial bladder cancer in the National Swedish Family Cancer Database.

Authors:  K Plna; K Hemminki
Journal:  J Urol       Date:  2001-12       Impact factor: 7.450

4.  Prevalence of monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Dirk R Larson; Matthew F Plevak; Janice R Offord; Angela Dispenzieri; Jerry A Katzmann; L Joseph Melton
Journal:  N Engl J Med       Date:  2006-03-30       Impact factor: 91.245

5.  A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew F Plevak; L Joseph Melton
Journal:  N Engl J Med       Date:  2002-02-21       Impact factor: 91.245

6.  Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden.

Authors:  Ola Landgren; Sigurdur Y Kristinsson; Lynn R Goldin; Neil E Caporaso; Cecilie Blimark; Ulf-Henrik Mellqvist; Anders Wahlin; Magnus Bjorkholm; Ingemar Turesson
Journal:  Blood       Date:  2009-01-30       Impact factor: 22.113

7.  Long-term follow-up of IgM monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Ellen D Remstein; Janice R Offord; Dirk R Larson; Matthew F Plevak; L Joseph Melton
Journal:  Blood       Date:  2003-07-24       Impact factor: 22.113

8.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

9.  Familial myeloma.

Authors:  Henry T Lynch; Kelly Ferrara; Bart Barlogie; Elizabeth A Coleman; Jane F Lynch; Dennis Weisenburger; Warren Sanger; Patrice Watson; Henry Nipper; Vinetta Witt; Stephan Thomé
Journal:  N Engl J Med       Date:  2008-07-10       Impact factor: 91.245

10.  Multiple myeloma and family history of cancer. A case-control study.

Authors:  C C Bourguet; S Grufferman; E Delzell; E R DeLong; H J Cohen
Journal:  Cancer       Date:  1985-10-15       Impact factor: 6.860
View more
  7 in total

Review 1.  The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.

Authors:  Niels W C J van de Donk; Antonio Palumbo; Hans Erik Johnsen; Monika Engelhardt; Francesca Gay; Henrik Gregersen; Roman Hajek; Martina Kleber; Heinz Ludwig; Gareth Morgan; Pellegrino Musto; Torben Plesner; Orhan Sezer; Evangelos Terpos; Anders Waage; Sonja Zweegman; Hermann Einsele; Pieter Sonneveld; Henk M Lokhorst
Journal:  Haematologica       Date:  2014-03-21       Impact factor: 9.941

Review 2.  Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies.

Authors:  Sigurdur Y Kristinsson; Lynn R Goldin; Magnus Björkholm; Jill Koshiol; Ingemar Turesson; Ola Landgren
Journal:  Haematologica       Date:  2009-07-07       Impact factor: 9.941

3.  Parental longevity and survival among patients with multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study.

Authors:  Ingigerður S Sverrisdóttir; Sigrún H Lund; Ingemar Turesson; Magnus Björkholm; Lynn R Goldin; Ola Landgren; Sigurður Y Kristinsson
Journal:  Br J Haematol       Date:  2019-03-24       Impact factor: 6.998

Review 4.  Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics.

Authors:  Alexandra J Greenberg; S Vincent Rajkumar; Celine M Vachon
Journal:  Blood       Date:  2012-02-21       Impact factor: 22.113

5.  Search for familial clustering of cancer in monoclonal gammopathy of unknown significance.

Authors:  K Hemminki; A Försti; J Sundquist; X Li
Journal:  Blood Cancer J       Date:  2016-07-08       Impact factor: 11.037

6.  Constitutional mutation in CDKN2A is associated with long term survivorship in multiple myeloma: a case report.

Authors:  Vallari Shah; Kevin D Boyd; Richard S Houlston; Martin F Kaiser
Journal:  BMC Cancer       Date:  2017-11-06       Impact factor: 4.430

7.  Monoclonal gammopathy of undetermined significance is associated with prostate cancer in a population-based cohort study.

Authors:  Nicola Hornung; Mirjam Frank; Nico Dragano; Jan Dürig; Ulrich Dührsen; Susanne Moebus; Raimund Erbel; Andreas Stang; Karl-Heinz Jöckel; Börge Schmidt
Journal:  Sci Rep       Date:  2021-09-29       Impact factor: 4.379
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.